[go: up one dir, main page]

MX2007002383A - Composiciones que contienen componentes agonistas alfa-2-adrenergicos. - Google Patents

Composiciones que contienen componentes agonistas alfa-2-adrenergicos.

Info

Publication number
MX2007002383A
MX2007002383A MX2007002383A MX2007002383A MX2007002383A MX 2007002383 A MX2007002383 A MX 2007002383A MX 2007002383 A MX2007002383 A MX 2007002383A MX 2007002383 A MX2007002383 A MX 2007002383A MX 2007002383 A MX2007002383 A MX 2007002383A
Authority
MX
Mexico
Prior art keywords
adrenergic agonist
alpha
components
agonist components
compositions containing
Prior art date
Application number
MX2007002383A
Other languages
English (en)
Inventor
Orest Olejnik
Richard Graham
Peter Bakhit
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2007002383A publication Critical patent/MX2007002383A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a composiciones utiles para mejorar la efectividad de los componentes agonistas alfa-2-adrenergicos que incluyen componentes portadores, componentes agonistas alfa-2-adrenergicos, componentes mejoradores de la solubilidad los cuales ayudan a solubilizar los componentes agonistas alfa-2-adrenergicos. En una modalidad, los componentes agonistas alfa-2-adrenergicos incluyen los agonistas alfa-2-adrenergicos. En otra modalidad, los componentes mejoradores de la solubilidad incluyen povidona y alcohol polivinilico.
MX2007002383A 2004-08-27 2005-08-17 Composiciones que contienen componentes agonistas alfa-2-adrenergicos. MX2007002383A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/928,906 US20050026924A1 (en) 2000-07-14 2004-08-27 Compositions containing alpha-2-adrenergic agonist components
PCT/US2005/029707 WO2006026215A1 (en) 2004-08-27 2005-08-17 Compositions containing alpha-2-adrenergic agonist components

Publications (1)

Publication Number Publication Date
MX2007002383A true MX2007002383A (es) 2007-05-15

Family

ID=35589384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002383A MX2007002383A (es) 2004-08-27 2005-08-17 Composiciones que contienen componentes agonistas alfa-2-adrenergicos.

Country Status (8)

Country Link
US (1) US20050026924A1 (es)
JP (2) JP2008511628A (es)
AU (1) AU2005280259A1 (es)
BR (1) BRPI0514723B8 (es)
CA (1) CA2578784C (es)
MX (1) MX2007002383A (es)
NZ (1) NZ599669A (es)
WO (1) WO2006026215A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8293742B2 (en) 2008-08-01 2012-10-23 Alpha Synergy Development, Inc. Preferential vasoconstriction compositions and methods of use
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
WO2011127151A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
AU2018240462C1 (en) * 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
WO2019112030A1 (ja) * 2017-12-08 2019-06-13 千寿製薬株式会社 水溶性高分子を含む水性液剤
JP6730500B2 (ja) * 2018-10-01 2020-07-29 千寿製薬株式会社 水性液剤
JP6797992B1 (ja) * 2019-09-30 2020-12-09 千寿製薬株式会社 水性液剤
JP6901619B2 (ja) * 2019-09-30 2021-07-14 千寿製薬株式会社 水性液剤
GR1010024B (el) 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
JP7002692B2 (ja) * 2020-11-18 2022-02-04 千寿製薬株式会社 水性液剤

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154119B (de) * 1961-11-30 1963-09-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4499077A (en) * 1981-02-03 1985-02-12 Stockel Richard F Anti-microbial compositions and associated methods for preparing the same and for the disinfecting of various objects
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5352796A (en) * 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JP3527256B2 (ja) * 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
JP3683908B2 (ja) * 1993-10-13 2005-08-17 アラーガン、インコーポレイテッド （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
DK0735877T3 (da) * 1993-12-17 2000-11-06 Procter & Gamble 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister.
US5994110A (en) * 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
AU7326901A (en) * 2000-07-14 2002-01-30 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
RU2291685C2 (ru) * 2000-07-14 2007-01-20 Аллерган Инк. Композиции, содержащие терапевтически активные компоненты, обладающие повышенной растворимостью
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions

Also Published As

Publication number Publication date
CA2578784C (en) 2015-02-17
BRPI0514723A (pt) 2008-06-24
CA2578784A1 (en) 2006-03-09
WO2006026215A1 (en) 2006-03-09
BRPI0514723A8 (pt) 2018-05-08
NZ599669A (en) 2013-11-29
JP2012246304A (ja) 2012-12-13
AU2005280259A1 (en) 2006-03-09
US20050026924A1 (en) 2005-02-03
BRPI0514723B8 (pt) 2021-05-25
JP2008511628A (ja) 2008-04-17
BRPI0514723B1 (pt) 2020-12-22

Similar Documents

Publication Publication Date Title
NO20024221D0 (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
TW200732349A (en) Anti-OX40L antibodies and methods using same
UY26970A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos
TW200639180A (en) PYY agonists and uses thereof
SG165314A1 (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
MX2007002383A (es) Composiciones que contienen componentes agonistas alfa-2-adrenergicos.
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
AP2005003383A0 (en) Aminoheteroaryl compounds as protein kinase inhibitors.
SG144146A1 (en) Adenosine receptor agonists
PA8792401A1 (es) Fenilendiaminas
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
EA200801430A1 (ru) Производные триазола
WO2007120333A3 (en) Tetracyclic kinase inhibitors
TW200621160A (en) Anti-termite agent
WO2005041904A3 (en) Inhibitors of coronavirus protease and methods of use thereof
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
EA200602017A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
LT2003075A (en) Inhibitor of monoamine uptake
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
MX2007009914A (es) Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal